Reply to Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use"

Houchen Lyu^{1

2}, Sizheng S Zhao^{1

3}, Daniel H Solomon^{1

4}

Affiliations

¹ Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, United States.
² China National Clinical Research Center of Musculoskeletal Diseases, Beijing, China.
³ Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom.
⁴ Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States.

Comment

Houchen Lyu et al. J Clin Endocrinol Metab. 2020.

. 2020 May 1;105(5):dgz123.

doi: 10.1210/clinem/dgz123.

Houchen Lyu^{1

2}, Sizheng S Zhao^{1

3}, Daniel H Solomon^{1

4}

¹ Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, United States.
² China National Clinical Research Center of Musculoskeletal Diseases, Beijing, China.
³ Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom.
⁴ Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States.

No abstract available

Comment on

Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
Lyu H, Zhao SS, Yoshida K, Tedeschi SK, Xu C, Nigwekar SU, Leder BZ, Solomon DH. Lyu H, et al. J Clin Endocrinol Metab. 2019 Nov 1;104(11):5611-5620. doi: 10.1210/jc.2019-00924. J Clin Endocrinol Metab. 2019. PMID: 31265071 Free PMC article.
Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use".
Geusens P, Marín F, Kendler DL. Geusens P, et al. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz122. doi: 10.1210/clinem/dgz122. J Clin Endocrinol Metab. 2020. PMID: 31650166 No abstract available.